Michael Wallisch

Michael Wallisch

Auto-generated profile, based on publicly available information

Michael Wallisch

Aronora, Inc, Portland, OR

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2003 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
AMAmom Ruhikanta Meetei
Amom Ruhikanta Meetei
JWJohan P de Winter
Johan P de Winter
AMAnnette L Medhurst
Annette L Medhurst
MWMichael Wallisch
Michael Wallisch
QWQuinten Waisfisz
Quinten Waisfisz
WWWeidong Wang
Weidong Wang

1 May 2003 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
AMAmom Ruhikanta Meetei
Amom Ruhikanta Meetei
SSSalvatore Sechi
Salvatore Sechi
MWMichael Wallisch
Michael Wallisch
DYDafeng Yang
Dafeng Yang
MYMary K. Young
Mary K. Young
WWWeidong Wang
Weidong Wang
Bloom syndrome (BS) is a genetic disorder associated with dwarfism, immunodeficiency, reduced fertility, and an elevated risk of cancer. To investigate the mechanism of this disease, we isolated from human HeLa extracts three complexes containing the helicase defective in BS, BLM. Interestingly, one of the complexes, termed BRAFT, also contains five of the Fanconi anemia (FA) complementation group proteins (FA proteins). FA resembles BS in genomic instability and cancer predisposition, but most of its gene products have no known biochemical activity, and the molecular pathogenesis of the disease is poorly understood. BRAFT displays a DNA-unwinding activity, which requires the presence of BLM because complexes isolated from BLM-deficient cells lack such an activity. The complex also contains topoisomerase IIIα and replication protein A, proteins that are known to interact with BLM and could facilitate unwinding of DNA. We show that BLM complexes isolated from an FA cell line have a lower molecular mass. Our study provides the first biochemical characterization of a multiprotein FA complex and suggests a connection between the BLM and FA pathways of genomic maintenance. The findings that FA proteins are part of a DNA-unwinding complex imply that FA proteins may participate in DNA repair.

1 August 1997 in Cell
Verified
Journal Article
Closed access
JGJosef-Karl Gerber
Josef-Karl Gerber
EGEric Gögel
Eric Gögel
CBChristian Berger
Christian Berger
MWMichael Wallisch
Michael Wallisch
FMFriedemann Müller
Friedemann Müller
FGFriedrich Grummt
Friedrich Grummt

2 December 2021 in Blood
Verified
Journal Article
Open access
PDF file
CLChristina U. Lorentz
Christina U. Lorentz
ETErik I. Tucker
Erik I. Tucker
NVNorah G. Verbout
Norah G. Verbout
JSJoseph J. Shatzel
Joseph J. Shatzel
SOSven R. Olson
Sven R. Olson
AGAndrás Gruber
András Gruber
End-stage renal disease (ESRD) patients on chronic hemodialysis have repeated blood exposure to artificial surfaces that can trigger clot formation within the hemodialysis circuit. Dialyzer clotting can lead to anemia despite erythropoietin and iron supplementation. Unfractionated heparin prevents clotting during hemodialysis, but it is not tolerated by all patients. Although heparin-free dialysis is performed, intradialytic blood entrapment can be problematic. To address this issue, we performed a randomized, double-blind, phase 2 study comparing AB023, a unique antibody that binds factor XI (FXI) and blocks its activation by activated FXII, but not by thrombin, to placebo in 24 patients with ESRD undergoing heparin-free hemodialysis. Patients were randomized to receive a single predialysis dose of AB023 (0.25 or 0.5 mg/kg) or placebo in a 2:1 ratio, and safety and preliminary efficacy were compared with placebo and observations made prior to dosing within each treatment arm. AB023 administration was not associated with impaired hemostasis or other drug-related adverse events. Occlusive events requiring hemodialysis circuit exchange were less frequent and levels of thrombin-antithrombin complexes and C-reactive protein were lower after AB023 administration compared with data collected prior to dosing. AB023 also reduced potassium and iron entrapment in the dialyzers, consistent with less blood accumulation within the dialyzers. We conclude that despite the small sample size, inhibition of contact activation–induced coagulation with AB023 was well tolerated and reduced clotting within the dialyzer. This trial was registered at www.clinicaltrials.gov as #NCT03612856.

1 April 2019 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
CLChristina U. Lorentz
Christina U. Lorentz
NVNorah G. Verbout
Norah G. Verbout
MWMichael Wallisch
Michael Wallisch
MHMatthew W. Hagen
Matthew W. Hagen
JSJoseph J. Shatzel
Joseph J. Shatzel
ETErik I. Tucker
Erik I. Tucker
Objective—: Factor XI (FXI) contributes to thrombotic disease while playing a limited role in normal hemostasis. We generated a unique, humanized anti-FXI antibody, AB023, which blocks factor XIIa-mediated FXI activation without inhibiting FXI activation by thrombin or the procoagulant function of FXIa. We sought to confirm the antithrombotic activity of AB023 in a baboon thrombosis model and to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adult subjects. Approach and Results—: In a primate model of acute vascular graft thrombosis, AB023 reduced platelet and fibrin accumulation within the grafts by >75%. To evaluate the safety of AB023, we performed a first-in-human study in healthy adult volunteers without any serious adverse events. Overall, 10 of 21 (48%) subjects experienced 20 treatment-emergent adverse events, with 7 of 16 (44%) subjects following active treatment and 3 of 5 (60%) subjects following placebo. AB023 did not increase bleeding or prothrombin times. Anticoagulation was verified by a saturable ≈2-fold prolongation of the partial thromboplastin time for over 1 month after the highest dose. Conclusions—: AB023, which inhibits contact activation-initiated blood coagulation in vitro and experimental thrombus formation in primates, produced a dose-dependent duration of limited anticoagulation without drug-related adverse effects in a phase 1 trial. When put in context with earlier observations suggesting that FXI contributes to venous thromboembolism and cardiovascular disease, although contributing minimally to hemostasis, our data further justify clinical evaluation of AB023 in conditions where contact-initiated FXI activation is suspected to have a pathogenic role. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT03097341.

1 January 2006 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
ASAlexandra Sobeck
Alexandra Sobeck
SSStacie Stone
Stacie Stone
VCVincenzo Costanzo
Vincenzo Costanzo
BGBendert de Graaf
Bendert de Graaf
TRTanja Reuter
Tanja Reuter
MHMaureen E. Hoatlin
Maureen E. Hoatlin
Fanconi anemia (FA) is a multigene cancer susceptibility disorder characterized by cellular hypersensitivity to DNA interstrand cross-linking agents such as mitomycin C (MMC). FA proteins are suspected to function at the interface between cell cycle checkpoints, DNA repair, and DNA replication. Using replicating extracts from Xenopus eggs, we developed cell-free assays for FA proteins (xFA). Recruitment of the xFA core complex and xFANCD2 to chromatin is strictly dependent on replication initiation, even in the presence of MMC indicating specific recruitment to DNA lesions encountered by the replication machinery. The increase in xFA chromatin binding following treatment with MMC is part of a caffeine-sensitive S-phase checkpoint that is controlled by xATR. Recruitment of xFANCD2, but not xFANCA, is dependent on the xATR-xATR-interacting protein (xATRIP) complex. Immunodepletion of either xFANCA or xFANCD2 from egg extracts results in accumulation of chromosomal DNA breaks during replicative synthesis. Our results suggest coordinated chromatin recruitment of xFA proteins in response to replication-associated DNA lesions and indicate that xFA proteins function to prevent the accumulation of DNA breaks that arise during unperturbed replication.